NCT02399202View on ClinicalTrials.gov

A Phase I Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Renal Function

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 6, 2015

Primary Completion Date

March 21, 2016

Study Completion Date

March 21, 2016

Conditions
Renal Impairment
Interventions
DRUG

osilodrostat

Trial Locations (2)

1612

Novartis Investigative Site, Sofia

14050

Novartis Investigative Site, Berlin

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY